NCT07607379Not yet recruiting
Robotic Dog Intervention on Emotional Well-Being and Quality of Life
Effectiveness and Feasibility of a Robotic Dog Intervention on Emotional Well-Being and Quality of Life in Pediatric Patients With Hematological Malignancies Undergoing HSCT
Source: ClinicalTrials.gov · Last updated 26 May 2026
Brief summary (registry, in English)
The hematopoietic stem cell transplantation (HSCT) process imposes a substantial psychological burden, leading to impaired emotional well-being due to intensive treatment, isolation, and immunosuppression. Patients often experience social withdrawal, loneliness, and loss of control, which may result in persistent anxiety, depressive symptoms, and reduced quality of life (QoL) if unaddressed. This study aims to evaluate the effectiveness, feasibility, and acceptability of an AI-powered robotic dog in improving emotional well-being and QoL in pediatric patients undergoing HSCT.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 28 (estimated)
- First submitted
- 18 May 2026
- Start date
- 1 Jul 2026
- Primary completion date
- 1 Apr 2028
- Lead sponsor
- Koç University
- Diseases
- Childhood cancers
- NCT number
- NCT07607379
What you commit to
- Study type: Interventional
- Planned participants: 28
- From 1 Jul 2026 to the primary completion date, 1 Apr 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Severe cognitive impairment or neurodevelopmental conditions preventing meaningful interaction or self-report
- Acute neurological conditions, delirium, or severe psychiatric crisis (e.g., acute agitation, suicidal ideation)
- Requirement for intensive care, invasive ventilation, or a clinically unstable condition
- Additional infection control restrictions prevent the placement or use of the robotic dog in the isolation room
Other
- Severe visual, hearing, or motor impairments that prevent interaction with the robotic dog
- Anticipated early discharge, transfer, or inability to complete follow-up assessments
- Severe fear, intolerance, or refusal to interact with robotic or electronic devices
Who the study is looking for
- Pediatric patients aged 8-15 years
- Diagnosed with a hematological malignancy and undergoing hematopoietic stem cell transplantation
- Hospitalized in a protective isolation room during the post-transplant inpatient period
- Expected to remain hospitalized under isolation for approximately 30 days post-transplant
- Able to understand and respond to Turkish-language self-report questionnaires
- Clinically stable and deemed eligible for participation by the treating clinical team
- Able to interact with the robotic dog at a basic functional level
Age in the registry: 8 years to 15 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.